First Quarter 2026 Results
Showing 274 search results
Grifols doses first participant in Phase 3 study evaluating novel subcutaneous therapy for alpha1-antitrypsin deficiency
Grifols discloses transfers of value made to European healthcare professionals and healthcare organizations in 2025
Grifols announces a next-generation automated system to enhance efficiency and flexibility in transfusion medicine laboratories
Shareholders approve key resolutions at the 2026 Annual General Shareholders’ Meeting
Grifols launches FESILTY™ (fibrinogen, human-chmt) in the U.S.
Grifols Egypt continues its growth plan through 2029 with an additional investment of €180 million
Publications
Links to our latest financial and sustainability reports and other recent publications.
Financial Report
Explore our last financial and earnings annual report.
Sustainability Report
Integrated and Sustainability Annual Report.
Position Paper
The differential value of plasma-derived medicinal products (PDMPs).
Press Kit
Explore our Press Kit to find key facts and figures on Grifols.
Media Contacts
If you're a journalist or media professional with a question, contact our media relations team.